In the blood-brain barrier market, Japanese companies are positioned as limited suppliers and have little presence as major suppliers. This report examines the situation in which overseas companies lead the market and the potential factors that could enable Japanese companies to enter it.
This report examines the current position of Japanese companies and the competitive landscape surrounding the blood-brain barrier market. Japanese companies are not currently positioned as major suppliers in the BBB market, and the analysis explores the possibility of their entry as suppliers.
BIOASIS Technologies Inc. and Denali Therapeutics Inc. are among the major companies in the blood-brain barrier market. Eisai is an exceptional example among Japanese companies, but direct supplies of underlying technologies and devices remain limited.
The challenges include mounting pricing pressure and low-cost competition from companies in emerging markets, competition over research and development speed and talent acquisition, and strategic decisions concerning the regulatory environment and intellectual property protection.
Going forward, investment and acquisitions by major pharmaceutical companies may advance, leading to greater integration and cost reduction in blood-brain barrier-related technologies. Regulatory compliance must be balanced with safety and immunogenicity, which is expected to be the key issue.